Diabetic Neuropathic Pain Treatment Landscape 2024: Comprehensive Insights About 10+ Companies and 12+ Pipeline Drugs - Product Type, Stage, Route of Administration, and Molecule Type Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Neuropathic Pain - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Diabetic Neuropathic...

Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain - AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals New York, USA, May 04, 2023 (GLOBE NEWSWIRE) -- Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain - AstraZeneca, Eli Lilly and Company,...

Trevena Reports Second Quarter 2021 Results Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...

Trevena Reports First Quarter 2021 Results -- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...